GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update
August 04 2021 - 9:00AM
via NewMediaWire --
GeoVax Labs,
Inc. (Nasdaq: GOVX) (“GeoVax” or the “Company”), a
biotechnology company developing human immunotherapies and vaccines
against infectious diseases and cancer, announces today that it
will report second quarter 2021 financial results on Wednesday,
August 11, 2021 after the market closes.
Management will host a conference call at 4:30 p.m. ET on
Wednesday, August 11, 2021 to review financial results and provide
an update on corporate developments. Following management’s
formal remarks, there will be a question and answer session.
Participants are asked to pre-register for the call via the
following link:
https://dpregister.com/sreg/10159241/ebf4d52ffa
Please note that registered participants will receive their
dial-in number upon registration and will dial directly into the
call without delay. Those without Internet access or who are
unable to pre-register may dial in by calling 1-866-777-2509
(domestic) or 1-412-317-5413 (international). All callers
should dial in approximately 10 minutes prior to the scheduled
start time and ask to be joined into the GeoVax Labs call.
The conference call will be available through a live webcast
found here:
https://services.choruscall.com/mediaframe/webcast.html?webcastid=xxw5fkQ6
A webcast replay of the call will be available via the same link
as the live webcast approximately one hour after the end of the
call through November 11, 2021. A telephonic replay of the
call can be accessed by calling 1-877-344-7529 (domestic) or
1-412-317-0088 (international) and using access code 10159241.
The telephonic replay will be available until August 25,
2021.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing human vaccines against infectious diseases and cancer
using a novel patented Modified Vaccinia Ankara-Virus Like Particle
(MVA-VLP) based vaccine platform. On this platform, MVA, a large
virus capable of carrying several vaccine antigens, expresses
proteins that assemble into VLP immunogens in the person receiving
the vaccine. The production of VLPs in the person being vaccinated
can mimic virus production in a natural infection, stimulating both
the humoral and cellular arms of the immune system to recognize,
prevent, and control the target infection. The MVA-VLP derived
vaccines can elicit durable immune responses in the host similar to
a live-attenuated virus, while providing the safety characteristics
of a replication-defective vector.
GeoVax’s current development programs are focused
on preventive vaccines against COVID-19, HIV, Zika Virus,
hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and
malaria, as well as therapeutic vaccines against multiple cancers.
The Company has designed a preventive HIV vaccine candidate to
fight against the subtype of HIV prevalent in the commercial
markets of the Americas, Western Europe, Japan, and Australia;
human clinical trials for this program are managed by the HIV
Vaccine Trials Network (HVTN) with the support of the National
Institutes of Health (NIH). GeoVax’s HIV vaccine is also part a
separate collaborative effort to apply its vaccine approach toward
a functional cure for HIV.
Cautionary Note Regarding Forward-Looking
Statements
This release and the related conference call contain
forward-looking statements regarding GeoVax’s business plans and
financial results. The words “believe,” “may,” “estimate,”
“continue,” “anticipate,” “intend,” “should,” “plan,” “could,”
“target,” “potential,” “is likely,” “will,” “expect” and similar
expressions, as they relate to us, are intended to identify
forward-looking statements. We have based these forward-looking
statements largely on our current expectations and projections
about future events and financial trends that we believe may affect
our financial condition, results of operations, business strategy
and financial needs. Actual results may differ materially from
those included in these statements due to a variety of factors,
including whether: GeoVax can develop and manufacture its vaccines
with the desired characteristics in a timely manner, GeoVax’s
vaccines will be safe for human use, GeoVax’s vaccines will
effectively prevent targeted infections in humans, GeoVax’s
vaccines will receive regulatory approvals necessary to be licensed
and marketed, GeoVax raises required capital to complete vaccine
development, there is development of competitive products that may
be more effective or easier to use than GeoVax’s products, GeoVax
will be able to enter into favorable manufacturing and distribution
agreements, the impact of the COVID-19 pandemic continues, and
other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our
registration statement on Form S-3 and the periodic reports on Form
10-Q and Form 10-K that we have filed and will file with the SEC.
Any forward-looking statement made by us herein speaks only as of
the date on which it is made. Factors or events that could cause
our actual results to differ may emerge from time to time, and it
is not possible for us to predict all of them. We undertake no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future developments or
otherwise, except as may be required by
law.
GeoVax Labs, Inc. 6783847220 investor@geovax.com
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Aug 2024 to Sep 2024
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Sep 2023 to Sep 2024